We are Sorry, This Page doesn't Exist
AbbVie"s RA Candidate Meets Primary Endpoints in Phase III
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication. AbbVie Inc. ABBV has anno.....»»
AbbVie: Upadacitinib meets primary, secondary endpoints in Phase 3 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
AbbVie says RINVOQ meets primary, key secondary endpoints in Phase 3 study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
AbbVie says Rinvoq meets primary, secondary endpoints in Phase 3 PA study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
The Daily Biotech Pulse: ViiV"s Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) read more.....»»
Ironwood"s Linzess Lowers Abdominal Symptoms in IBS-C Patients
Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pa.....»»
J&J"s (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug.....»»
BioCryst Down Despite Hereditary Angioedema Study Meets Goal
BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this .....»»
Aldeyra"s Eye Drug Meets Main Goal in Study, Shares Surge
Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with a.....»»
More Data Needed On Proteostasis Therapeutics" Cystic Fibrosis Candidate, RBC Says In Downgrade
After Proteostasis Therapeutics Inc (NASDAQ: PTI)’s mixed Phase 2 results from a study of its PTI-801 cystic fibrosis transmembrane conductance regulator, RBC Latest Ratings for PTI DateF.....»»
Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval
Global Blood Therapeutics Inc (NASDAQ: GBT) shares were trading down off the open Wednesday after the company released data from its sickle cell disease candidate. read more.....»»
KemPharm Stock Down Despite Positive Data on ADHD Candidate
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study. KemPharm, Inc. KMPH announced positive t.....»»
Roche"s Tecentriq Met Primary Goal in First-Line NSCLC Study
Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»
Novartis Breast Cancer Drug Meets Primary Goal in Phase III
Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients. Novartis AG NVS announced that the phas.....»»
AbbVie Posts Positive Data on Elagolix for Uterine Fibroids
AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for .....»»
Vertex"s (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy. .....»»
Amgen/Allergan"s Rituxan Biosimilar Meets Goal in Phase III
Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798.....»»